Representativeness Is a Design Decision

Artificial intelligence is one of the most significant opportunities diagnostic medicine has had in decades. Whether it closes existing gaps in care or quietly widens them depends less on the sophistication of the model than on a single upstream question. Do the data and validation behind the tool represent the patients it will actually serve?

That question framed a systematic review I conducted on AI in breast cancer detection. The work synthesized peer-reviewed studies published between 2020 and 2024 and was recognized by New England HIMSS. It compared AI-based methods against conventional imaging across mammography, ultrasound, and MRI, and looked closely at where these tools succeed, where they fail, and why.

Across the literature, AI consistently improved diagnostic accuracy, reduced false positives and false negatives, and eased the cognitive load on radiologists. The clearest gains appeared in exactly the cases conventional screening handles least well, including dense breast tissue, where standard mammography misses a meaningful share of cancers.

The pattern was consistent on one further point. Used as a second reader rather than a replacement, AI strengthened detection while leaving clinical judgment intact. The most defensible deployments treated the model as decision support, not as a substitute for the radiologist.

One limitation surfaced more consistently than any other: generalizability. Models performed well on the populations they were trained and validated on, then quietly slipped everywhere else. Datasets skewed toward particular demographics and disease presentations produced tools that underperformed in the very groups they underrepresented.

The risk in this category is not that the technology fails loudly. It is that it works for some patients and fails quietly for others, while everyone deploying it assumes the math is neutral. That failure is invisible unless someone forces it into the open at the validation stage.

The corrective measures recurred across studies, and they point in one direction. Validate across multiple centers and multiple vendors rather than a single institution. Use approaches such as federated learning to train on diverse populations without compromising patient privacy. Recruit validation cohorts that reflect the patients a tool will serve, not the patients who were easiest to enroll.

In other words, build representativeness into the architecture from the first dataset decision, rather than adding it at the point of clearance. By the time a tool reaches regulatory review, the decisions that determine who it serves well have already been made.

Bias in clinical data does not disappear when it is fed into a model. It scales. An algorithm trained on a narrow foundation does not neutralize that history, it accelerates it, and it does so dressed up as objective because it is data driven. Getting this right is a design problem before it is a regulatory one.

This is the principle I now carry into the clinical AI I build for post-acute care. Representativeness, transparency, and human oversight are treated as architecture, set at the start, rather than as features bolted on once the tool is already in front of patients. The companies and clinicians who do that work early will not have to redo it under pressure later.